Cipla is currently trading at Rs 1463.90, showing a robust increase of 3.42% today. The 7-day exponential moving average at Rs 1495.45 suggests a positive trend in its recent performance. Cipla is ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles. Equivalent to Bristol Myers Squibb's Abraxane, it treats various cancers and is ...

Mumbai: Cipla has announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (‘ANDA’) submitted for ...

Cipla share price: Pharmaceutical major Cipla shares were in demand on Friday, April 11, 2025, as the scrip popped up to 5.11 per cent to hit an intraday high of ₹1,488.80, upon securing USFDA ...

Shares of Cipla Ltd. opened with gains of as much as 5% on Friday, after the drugmaker announced that it has received final approval from the US Food and Drug Administration (USFDA) for its ...

Cipla receives USFDA approval for its generic cancer treatment drug, paclitaxel protein-bound particles, a therapeutic equivalent to Bristol Myers Squibb's Abraxane. The drug is expected to launch in ...

Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ...

NEW DELHI, Apr 11: Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the ...

Pharma company Cipla has announced the date for its earnings release for the fourth quarter and full year ended March 31, 2025. In an exchange filing, the company said that a meeting of the Board of ...

With trade tensions between the US and China rising, there is growing speculation over whether China will sell its huge stockpile of US Treasury bonds to strike back. Often referred to by analysts as ...